vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Lucid Group, Inc. (LCID). Click either name above to swap in a different company.

Lucid Group, Inc. is the larger business by last-quarter revenue ($522.7M vs $487.7M, roughly 1.1× CLOVER HEALTH INVESTMENTS, CORP.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -155.7%, a 145.6% gap on every dollar of revenue. On growth, Lucid Group, Inc. posted the faster year-over-year revenue change (122.9% vs 44.7%). CLOVER HEALTH INVESTMENTS, CORP. produced more free cash flow last quarter ($-69.0M vs $-1.2B). Over the past eight quarters, Lucid Group, Inc.'s revenue compounded faster (74.0% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Lucid Group, Inc., is an American automotive and technology company that manufactures electric vehicles and supplies advanced electric vehicle powertrain systems. The company is headquartered in Newark, California. In September 2021, the company began producing the Lucid Air sedan at its factory in Casa Grande, Arizona. Production of its second model, the Lucid Gravity SUV, started in December 2024. Lucid also supplies and develops powertrain technology to other automakers, including Aston Ma...

CLOV vs LCID — Head-to-Head

Bigger by revenue
LCID
LCID
1.1× larger
LCID
$522.7M
$487.7M
CLOV
Growing faster (revenue YoY)
LCID
LCID
+78.2% gap
LCID
122.9%
44.7%
CLOV
Higher net margin
CLOV
CLOV
145.6% more per $
CLOV
-10.1%
-155.7%
LCID
More free cash flow
CLOV
CLOV
$1.2B more FCF
CLOV
$-69.0M
$-1.2B
LCID
Faster 2-yr revenue CAGR
LCID
LCID
Annualised
LCID
74.0%
18.6%
CLOV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
LCID
LCID
Revenue
$487.7M
$522.7M
Net Profit
$-49.3M
$-814.0M
Gross Margin
-80.7%
Operating Margin
-10.1%
-203.7%
Net Margin
-10.1%
-155.7%
Revenue YoY
44.7%
122.9%
Net Profit YoY
-123.2%
-104.9%
EPS (diluted)
$-8.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
LCID
LCID
Q4 25
$487.7M
$522.7M
Q3 25
$496.6M
$336.6M
Q2 25
$477.6M
$259.4M
Q1 25
$462.3M
$235.0M
Q4 24
$337.0M
$234.5M
Q3 24
$331.0M
$200.0M
Q2 24
$356.3M
$200.6M
Q1 24
$346.9M
$172.7M
Net Profit
CLOV
CLOV
LCID
LCID
Q4 25
$-49.3M
$-814.0M
Q3 25
$-24.4M
$-978.4M
Q2 25
$-10.6M
$-539.4M
Q1 25
$-1.3M
$-366.2M
Q4 24
$-22.1M
$-397.2M
Q3 24
$-9.2M
$-992.5M
Q2 24
$7.4M
$-643.4M
Q1 24
$-19.2M
$-680.9M
Gross Margin
CLOV
CLOV
LCID
LCID
Q4 25
-80.7%
Q3 25
-99.1%
Q2 25
-105.0%
Q1 25
-97.2%
Q4 24
-89.0%
Q3 24
24.5%
-106.2%
Q2 24
30.3%
-134.5%
Q1 24
23.6%
-134.3%
Operating Margin
CLOV
CLOV
LCID
LCID
Q4 25
-10.1%
-203.7%
Q3 25
-4.9%
-279.9%
Q2 25
-2.2%
-309.5%
Q1 25
-0.3%
-294.4%
Q4 24
-6.4%
-312.6%
Q3 24
-2.7%
-385.2%
Q2 24
2.0%
-392.6%
Q1 24
-6.5%
-422.6%
Net Margin
CLOV
CLOV
LCID
LCID
Q4 25
-10.1%
-155.7%
Q3 25
-4.9%
-290.7%
Q2 25
-2.2%
-207.9%
Q1 25
-0.3%
-155.8%
Q4 24
-6.6%
-169.4%
Q3 24
-2.8%
-496.1%
Q2 24
2.1%
-320.8%
Q1 24
-5.5%
-394.2%
EPS (diluted)
CLOV
CLOV
LCID
LCID
Q4 25
$-8.26
Q3 25
$-3.31
Q2 25
$-0.28
Q1 25
$-0.24
Q4 24
$-0.20
Q3 24
$-0.41
Q2 24
$-0.34
Q1 24
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
LCID
LCID
Cash + ST InvestmentsLiquidity on hand
$78.3M
$1.6B
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$717.3M
Total Assets
$541.0M
$8.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
LCID
LCID
Q4 25
$78.3M
$1.6B
Q3 25
$2.3B
Q2 25
$2.8B
Q1 25
$3.6B
Q4 24
$194.5M
$4.0B
Q3 24
$288.0M
$3.5B
Q2 24
$254.8M
$3.2B
Q1 24
$208.3M
$4.0B
Stockholders' Equity
CLOV
CLOV
LCID
LCID
Q4 25
$308.7M
$717.3M
Q3 25
$340.9M
$1.8B
Q2 25
$344.2M
$2.4B
Q1 25
$336.1M
$3.2B
Q4 24
$341.1M
$3.9B
Q3 24
$342.2M
$2.7B
Q2 24
$324.9M
$3.5B
Q1 24
$292.5M
$4.2B
Total Assets
CLOV
CLOV
LCID
LCID
Q4 25
$541.0M
$8.4B
Q3 25
$559.7M
$8.8B
Q2 25
$575.0M
$8.9B
Q1 25
$583.7M
$9.2B
Q4 24
$580.7M
$9.6B
Q3 24
$653.0M
$8.5B
Q2 24
$674.2M
$8.2B
Q1 24
$671.8M
$8.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
LCID
LCID
Operating Cash FlowLast quarter
$-66.9M
$-916.4M
Free Cash FlowOCF − Capex
$-69.0M
$-1.2B
FCF MarginFCF / Revenue
-14.1%
-237.6%
Capex IntensityCapex / Revenue
0.4%
62.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$-3.8B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
LCID
LCID
Q4 25
$-66.9M
$-916.4M
Q3 25
$12.1M
$-756.6M
Q2 25
$5.4M
$-830.2M
Q1 25
$-16.3M
$-428.6M
Q4 24
$34.8M
$-533.1M
Q3 24
$50.0M
$-462.8M
Q2 24
$44.8M
$-507.0M
Q1 24
$25.9M
$-516.7M
Free Cash Flow
CLOV
CLOV
LCID
LCID
Q4 25
$-69.0M
$-1.2B
Q3 25
$11.4M
$-955.5M
Q2 25
$4.8M
$-1.0B
Q1 25
$-16.5M
$-589.9M
Q4 24
$33.3M
$-824.8M
Q3 24
$49.6M
$-622.5M
Q2 24
$44.4M
$-741.3M
Q1 24
$25.5M
$-714.9M
FCF Margin
CLOV
CLOV
LCID
LCID
Q4 25
-14.1%
-237.6%
Q3 25
2.3%
-283.9%
Q2 25
1.0%
-390.4%
Q1 25
-3.6%
-251.0%
Q4 24
9.9%
-351.8%
Q3 24
15.0%
-311.2%
Q2 24
12.5%
-369.6%
Q1 24
7.3%
-413.9%
Capex Intensity
CLOV
CLOV
LCID
LCID
Q4 25
0.4%
62.3%
Q3 25
0.1%
59.1%
Q2 25
0.1%
70.4%
Q1 25
0.0%
68.6%
Q4 24
0.5%
124.4%
Q3 24
0.1%
79.8%
Q2 24
0.1%
116.8%
Q1 24
0.1%
114.7%
Cash Conversion
CLOV
CLOV
LCID
LCID
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

LCID
LCID

LCNRV$287.2M55%
Other$80.4M15%
Related Party$74.4M14%
Regulatory Credits$34.2M7%
Warranty Provision$26.2M5%
Sale And Leaseback Transactions$15.2M3%
Other International$5.0M1%

Related Comparisons